Download this white paper to learn more about the challenges and the importance of neutralizing antibodies assays and immunogenicity strategy in drug development to assess and mitigate risk. Immunogenicity testing and immunoassays can be a crucial component of your product's development and success. IQVIA Laboratories services can meet your immunogenicity and immunoassay needs, from method development and validation, through sample analysis and customized reporting. Our scientists have extensive experience developing and validating variety of assays that support drug development including ELISA, Electrochemiluminescence (ECL), and cell-based immunoassays. At IQVIA Laboratories, we can develop and validate custom-designed assays as well as ensure the transfer of existing bioanalytical methods.
Complete the form below to access this white paper
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Automation within an ADME Laboratory
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Absolute Bioavailability Analysis Using Stable Isotopes
A Liquid Chromatography-Tandem Mass Spectrometry Approach
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
Bioanalytical & ADME Laboratory Services
Accelerate and enhance your discovery, preclinical and clinical programs
